


ALLOSTERIC BIOSCIENCE, INC.




Goal: Optimize Both Lifespan and Health-Span

Forward Looking Statement

The information contained in this communication is for information purposes only and may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements as to future operating results and plans that involve risks and uncertainties. We use words such as “expects”, “anticipates”, “believes”, “estimates”, the negative of these terms and similar expressions to identify forward looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason. This is neither a solicitation of investment nor an offer to sell and/or buy securities. References herein to “the Company,” “we,” “our,” “us” and similar words or phrases are references to Allosteric Bioscience and/or its subsidiaries, unless the context otherwise requires.

Global Need to Improve Aging

Globally, individuals of age 60 and over are expected to increase from 1 billion (in 2020) to 1.4 billion (in 2030), according to WHO.



Global Need to Improve Aging

Others Approach to Aging Research:


Diseases – Biopharmaceutical Industry

Aging Skin – Cosmetic Industry

Aging Body Parts–Transplants, Stem Cell

Longevity – Diet, Vitamins, Exercise

Allosteric Bioscience targets the **Aging Process** itself which has the potential to:



Founders, Scientific and Business Expertise

Arthur Bollon, PhD

- Founder
- Extensive expertise in all biomedical sciences including: Genetics, Genomics, Proteomics, Epigenetics
- Ph.D. from Rutgers and Postdoctoral Fellow at Yale University Medical School.
- Has formed six biotechnology companies including Co-Founder of Cytoclonal Pharmaceuticals where he was Chairman and CEO and which merged to form OPKO Health (market cap of approximately \$1.4 billion.)

Bruce Meyers

- Founder
- Has been involved in the formation and funding of six biotechnology companies including Co-Founder of Cytoclonal Pharmaceuticals which merged to form OPKO Health (market cap of approximately \$1.4 billion.)

Peter Sordillo, MD, PhD, MS

- Founder
- World leading Oncologist who has treated approximately 80,000 cancer patients
- Managed over 50 human clinical trials at centers such as Memorial Sloan Kettering
- Expertise and degrees in Quantum Physics
- Over 170 scientific publications
- Extensive expertise in all biomedical sciences including: Genetics. Genomics. Proteomics, Epigenetics

Dr. John Pople

- Former Collaborator and Chairman of the Advisory Board at Cytoclonal Pharmaceuticals, Inc.
- Nobel Prize in 1998 for pioneering Quantum Chemistry

Our Business Strategy

Partnership

Polaris, qb, a leader in Quantum Computing and Advanced AI for drug discovery. Equity investment and Contract Research for the Creation of Modulators of lead proteins involved in Aging and Longevity

Scientific Collaborators and Consultants

- Leaders in Aging and Longevity -
Dr. Barbara Slusher, Johns Hopkins University
(Licensing Complementary Technology – Slide 9)
Dr. Susan Michaelis, Johns Hopkins University

Commercial Development

Preferred Strategy is Partnering with Biopharma Companies and Licensing in Select Cases

We are focusing on 3 main Aging/Longevity Targets

Target 1

Sarcopenia – Muscle Wasting - Part of the Normal Aging Process and Serious Side Effect of Weight Loss and Diabetes Drugs, Cancer, ALS and other diseases

Target 2

**Progerin/Lamin A – Aging genetic disease
Progeria – focus on Normal Aging Complex**

Target 3

Tryptophan/KMO – Focus on key Aging enzyme in the toxic Kynurenine Pathway

Aging/Longevity Targets

Target 1: SARCOPENIA (Muscle Wasting)

- **Reduction in Muscle Mass and Function**
- **Major Part of the Normal Aging process**
- **Side Effect of Weight Loss and Diabetes Drugs**
- **Associated with various diseases such as Cancer, ALS and others**

Aging/Longevity Targets

Target 1: SARCOPENIA (Muscle Wasting)

- **Licensed Technology (LT) for Prevention/Treatment of SARCOPENIA from Johns Hopkins University**
- **LT was developed by Dr. Barbara Slusher and colleagues. She is Professor and Director of Johns Hopkins Drug Discovery. Prior to joining Johns Hopkins, she held positions such as Senior VP in the pharmaceutical industry and contributed to development of several FDA approved drugs**
- **[Click to view the Business Wire Sarcopenia Announcement](#)**

Target 1: SARCOPENIA (Muscle Wasting)

- **LT involves inhibitors of an enzyme termed GCPII for the treatment of Sarcopenia. Levels of GCPII increase with aging and can cause loss of muscle mass and function**
- **LT treatment in an animal model resulted in preservation of muscle and inhibition of Sarcopenia**
- **Preservation of muscle mass and function and inhibition of Sarcopenia could play a significant role in improving and optimizing aging and longevity**

Target 2: Progerin - Aging/Longevity Protein

- **Progerin is a defective protein generated by a mutated Lamin A gene. (Lamin A needed for nucleus functioning)**
- **Progerin causes the aging genetic disease Progeria. Progeria is a Rare premature rapid-aging genetic disease. Progeria Patients start aging in their early teens and typically die of a heart attack before 20.**
- **Progerin is also produced in normal individuals after the age of approximately 70 and part of normal aging process!**



New Scientific Advisory Board Member

Dr. Susan Michaelis joins Scientific Advisory Board 2-7-23

- Dr. Michaelis is a world authority on aging research including understanding the molecular basis of Progeria, a premature aging genetic disease.
- She is a Professor of Cell Biology in the Johns Hopkins University School of Medicine.
- Dr. Michaelis states in Business Wire that “Allosteric Bioscience has a unique angle on aging research and aims to improve both lifespan and health-span,” ([Press Release Link](#)).

Creation of Progerin Modulators using the QAB Platform

Identification	of critical Aging/Longevity Target – Progerin/LaminA
Created	a Targeted Library of 4 billion chemicals
Filtration	of Targeted Library based on molecular criteria
Selected	20 leads from the 4 billion library for each L1 and L2 <ul style="list-style-type: none">• Library L1 - Blood Brain Barrier leads• Library L2 - Non-Blood Brain Barrier leads
“ALM”	Analysis of leads for Modulation and Optimization of Aging and Longevity (SRA - Johns Hopkins University (Slide 14))

Johns Hopkins Sponsored Research Agreement

Dr. Susan Michaelis – Johns Hopkins School of Medicine Sponsored Research Agreement (SRA)

- **SRA involves analysis of Modulators created by ABI for Optimization of Aging and Longevity.**
- **Modulators were created using ABI's - QAB platform - using Quantum Computing, advanced AI integrated with biomedical sciences such as Genetics, Genomics, Systems Biology etc.**
- **[Press Release Link](#)**

Target 3: Tryptophan/KMO

- **Tryptophan is an α -amino acid that is used in the biosynthesis of proteins.**
- **Abnormal Tryptophan Metabolism – involved in Aging and Longevity as well as in Cancer, Stroke and Neurological Diseases.**
- **Founder has extensive expertise: Dr. Peter Sordillo has done extensive research on the tryptophan pathways and their relationship to diseases including Alzheimer's, Parkinson's, heart disease and cancer.**

Aging/Longevity Targets

BIOPHOTONICS, TRYPTOPHAN AND DISEASE

Edited by

LAURA A. SORDILLO
PETER P. SORDILLO



ELSEVIER



ACADEMIC PRESS

An imprint of Elsevier

ISBN 978-0-12-822790-9



9 780128 227909

Target 3: Tryptophan/KMO

We have shown that the shift in tryptophan metabolism from the serotonin-melatonin pathway (neuro - and cardio protective) to kynurenine pathway (where numerous toxic metabolites are formed), can cause age-related diseases such as:

- Cancer
- Myocardial Infarction
- Alzheimer's Disease
- Parkinson's Disease
- ALS
- Eye Diseases
- Auto-immune Disease
- Infectious Diseases
- Schizophrenia
- Recurrent Depression
- PTSD

Target 3: Tryptophan/KMO 2-Fold Increase in Longevity

- Other researchers have shown that Suppression of kynurenine pathway markedly Increases Longevity in fruit fly and yeast models; in C. elegans worm, longevity is increased 2-fold.
- We believe that the increases in longevity may be because these toxic kynurenines cause abnormal folding of proteins throughout the body (brain, heart, eye etc.) by:
 - 1) self-assembling and acting as “seeds” for abnormal folding, and
 - 2) by suppressing “chaperones” which guide normal folding. The abnormal protein folding results in formation of plaque in the heart, brain and other organs.

Target 3: Tryptophan/KMO Modulators of KMO

- **Using the QAB platform targeting Creation of Modulators of KMO – Key enzyme involved in Abnormal Tryptophan Metabolism.**
- **Designed to also cross the blood-brain barrier.**
- **Targeting a library of 4 billion possible agents to find the best drugs that suppress KMO. We believe that this could suppress the formation of toxic Kynurenines and reduce their negative effects on longevity.**

Summary

Our Unique Strategy for Optimization of Aging and Longevity

Aging Complex

Delineating and Controlling components of the Aging Complex which controls the Aging and Longevity Process

Platforms

- Sarcopenia (Muscle Wasting) Platform – Prevention, Treatment
- QAB Platform - The Revolutionary Quantum Computer and advanced AI integrated with the Biomedical Sciences - creating Modulators of the Aging and Longevity Targets and Process

Targets

- Sarcopenia – Muscle Wasting - Prevention. Treatment
- Progerin/Lamin A - Critical Aging/Longevity Protein Targets
- Tryptophan KMO - Normal Aging/Longevity Target - Reduce Aging Related Diseases

Summary

Contact Information

Arthur P. Bollon, PhD
President and Co-Founder
Allosteric Bioscience, Inc.
Tel: 469.585.7613
Email: arthurb@allostericbioscience.com

Bruce Meyers
Executive Chairman and Co-Founder
Allosteric Bioscience, Inc.
Tel: 646.391.7957
Email: bmeyers@allostericbioscience.com

www.allostericbioscience.com